Cheshire and Merseyside Cancer Alliance (NHS) has selected project portfolio management software leader, Bestoutcome, for its project, programme, and portfolio management. Following the assessment of leading PPM packages in the market, CMCA has finally settled on the company’s PM3.
As expressed by PMO Manager, Sarah Atherden, the alliance has selected PM3 due to its extensive utility in the NHS, its ease of usage and efficient and powerful reporting mechanisms. Even though NHS has some sound project management practices across the CMCA, it wanted to have a more consistent and standardized approach which could be supported and facilitated via PM3.
The tool’s capability of partitioning will enable every partner within the Alliance to keep their projects private, allowing various organizations to work on collaborated programmes that suit their requirements, added Atherden.
Reportedly, Cheshire and Merseyside Cancer Alliance stands at the forefront of the execution of NHS’s LTP (Long Term Plan) ambitions for cancer across its local system and also offers co-ordination and system oversight for cancer services via collaborative agreements with partners. The alliance has the objective of enhancing patient outcomes and improving performance against key operational standards, cite sources.
With regards to this deployment, Bestoutcome Director, David Walton, has expressed the company’s pleasure in having been chosen by Cheshire and Merseyside Cancer Alliance for helping to manage its programmes and projects. PM3 was apparently selected for helping to furnish a standardized approach to project management and to deliver a ‘single source of the Truth’ that would support visibility and consistency across programmes for all aspects of reporting.
Uninitiated, Bestoutcome is renowned for its tools in project, programme, and portfolio management services and always concentrates on the total outcome for ensuring successful business change. The company’s flagship PPM tool, PM3, is being deployed by a broad set of clients in the public, private, and charity sectors, state sources.
Source Credits:
Most Read
Biohaven Pharmaceutical Holding Company and Sosei Group Corporation have signed a collaboration and licensing agreement under which the form...
Adding to yet other initiatives and accomplishments in the medical fraternity, a California-based pathogen-protected blood component develop...
The first phase of installation is expected to be commenced in December 2020 nationwide. The Federal Government of Nigeria has recently sta...
Acquisitions, collaborations, and mergers have become a common practice in the medical and biotechnology sector in recent years. Speaking of...
Our Conrtributor
Technology giant- Apple Inc. has recently unveiled the ‘AirPods Max’, active noise-cance...
ZYIL1 stands out to be a novel oral small molecule NLRP3 inhibitor candidate which is expected to be...
Messaging services company, Gupshup has reportedly launched an all-new IP-based messaging channel wi...
© 2023 lunchwithapunch.com. All Rights Reserved.